No registrations found.
ID
Source
Brief title
Health condition
Psoriasis, Psoriatic Arthritis
Sponsors and support
Intervention
Outcome measures
Primary outcome
Main study endpoint will be the incidence rate of PsA in Pso patients in the setting of a university dermatology outpatient clinic.
Secondary outcome
Secondary endpoints will be the predictive values of several markers to predict the chance of development of PsA.
Background summary
Monocenter longitudinal observational study, following psoriasis patients until the development of psoriatic arthritis. Patients who were screened in the previous DAPPER-study will be followed up to 5 years, with a rheumatological check-up every year. Incidence rate of psoriatic arthritis will be the primary outcome. Secondary goals will be the detect predictors for the development of psoriatic arthritis, using the data from this and the previous DAPPER-study.
Study objective
Clinical characteristics of psoriasis can predict the development of psoriatic arthritis.
Study design
12-24-36-48-60 months (window + 6 months)
Intervention
None.
Inclusion criteria
* Diagnosis of cutaneous psoriasis
* Inclusion in DAPPER study
* Age 16 years or above
* Willing and able to comply with visits and study-related procedures
* Provide signed informed consent (IC)
Exclusion criteria
* Medical history with PsA
* Medical history with other immune-mediated or auto-immune rheumatological disease. For example, but not limited to: rheumatoid arthritis, systemic vasculitis, axial spondyloarthritis. Gout, fibromyalgia or osteo-arthritis are not excluded.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL9231 |
| Other | CMO Arnhem-Nijmegen : 2020-7088 |